Claritev Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTEV research report →
Range $40 – $73
Price Chart
About the company
Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations.
- CEO
- Travis S. Dalton
- IPO
- 2020
- Employees
- 3,000
- HQ
- McLean, VA, US
Get TickerSpark's AI analysis on CTEV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $312.13M
- P/E
- -1.36
- PEG
- -0.06
- P/S
- 0.37
- P/B
- -1.09
- EV/EBITDA
- 10.24
- Div Yield
- 0.00%
- Gross Margin
- 33.77%
- Op Margin
- 5.85%
- Net Margin
- -27.05%
- ROE
- 104.20%
- ROIC
- 1.02%
Latest fiscal year · YoY change
- Revenue
- $965.41M+3.7%
- Gross Profit
- $266.58M-61.4%
- Op Income
- $45.06M
- Net Income
- $-284,282,000+82.7%
- EPS
- $-17.30+83.0%
- OCF Growth
- +9.0%
- FCF Growth
- -16.8%
- 52W High
- $55.50
- 52W Low
- $11.50
- 50D MA
- $24.99
- 200D MA
- $25.37
- Beta
- 0.79
- RSI (14)
- 36
- Avg Volume
- 210.18K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Claritev delivered a strong Q3 beat with revenue, EBITDA, bookings, and cash flow all ahead of expectations, and raised full-year 2026 guidance while signaling at least $1.1 billion of revenue in 2027.· November 9, 2026
- Q3 revenue was $268.3 million, up 9.1% year over year and 4.2% sequentially; adjusted EBITDA was $162 million, up 4.4% year over year, with margin at 60.4%.
- Bookings were $27 million of ACV in Q3 and more than $100 million year to date; management now expects full-year ACV bookings of $115 million to $125 million.
- Full-year 2026 guidance was raised to $1.038 billion to $1.043 billion of revenue, $625 million to $630 million of adjusted EBITDA, and $10 million to $20 million of free cash flow.
- Claritev said it is about a year ahead of its March Investor Day plan and expects at least $1.1 billion of revenue in 2027.
- Claims Intelligence and NSA were the biggest drivers, while Payment & Revenue Integrity was pressured by a client transition but is expected to return to growth in 2027.
Total revenue in Q3 was $268.3 million, up 9.1% year over year and 4.2% sequentially. Adjusted EBITDA was $162 million, up 4.4% year over year, and adjusted EBITDA margin was 60.4% versus 63.1% a year ago. For the first nine months, revenue was $770.5 million, up 7.2% year over year, and adjusted EBITDA was $464.7 million, up 3% with a 60.3% margin. The company booked $27 million of ACV in Q3, brought year-to-date bookings to more than $100 million, and ended with $10.1 million of unrestricted cash and $95 million drawn on its revolver. Full-year 2026 guidance was raised to revenue of $1.038 billion to $1.043 billion, adjusted EBITDA of $625 million to $630 million, free cash flow of $10 million to $20 million, and capex of $165 million to $170 million. Q4 revenue is expected to be $270 million at the midpoint, with operating cash flow of $110 million to $120 million and free cash flow of $74 million to $84 million. Management also said 2027 revenue should be at least $1.1 billion.
Travis Dalton framed the quarter as further proof that Claritev’s horizontal product and vertical market strategy is working, emphasizing that the company is “delivering on the turn and the way up.” He said the business is gaining momentum across payer, public sector, provider, and TPA markets, with 46 net new clients over two years and bookings increasingly diversified beyond the core payer market. He also highlighted new AI-enabled products, including Claritev Healthcare Intelligence and transparency-based pricing, and said the company is building toward “a breakout 2027” with a stronger competitive position and a durable growth trajectory.
Doug Garis emphasized that the company beat internal expectations on revenue, adjusted EBITDA, and free cash flow, and that Claritev is running about a year ahead of its March Investor Day plan. He cited Q3 revenue of $268.3 million, adjusted EBITDA of $162 million, and trailing-12-month revenue above $1 billion for the first time since Q1 2023. He also pointed to $18.1 million of operating cash flow in Q3, a $25.8 million free cash flow use in the quarter, $230.7 million of unlevered free cash flow in the first nine months, and a 50% nine-month adjusted cash conversion rate, while reiterating the goal of greater than 50% full-year cash conversion. He noted $10.1 million of unrestricted cash, $95 million drawn on the revolver, and net leverage of 7.7x, and said the company expects R&D intensity to normalize over time as transformation spending rolls off.
Analysts focused on the durability of Claims Intelligence growth, the source of the 2027 revenue step-up, and why Payment & Revenue Integrity underperformed. Management said much of the strength in Claims Intelligence came from NSA volumes tied to an early 2026 client win, but also argued that the business still has room to grow as healthcare shifts outside the “4 walls” and as value per claim continues to rise. On Payment & Revenue Integrity, Doug Garis said the weakness was mostly due to a client transition from clinical negotiations to Claims Intelligence, with the business excluding that piece roughly flat in the quarter and expected to return to growth in 2027. Questions also probed AI and headcount; management said AI is being used to improve workflow efficiency and internal productivity, but they did not give line-item headcount targets.
The call showed broad operating momentum: revenue and EBITDA beat expectations, bookings exceeded $100 million year to date, and management raised full-year guidance. Claritev also said its booking mix is becoming more diversified across verticals and that 2027 revenue should be at least $1.1 billion, signaling confidence in the durability of growth.
A meaningful part of the upside still appears tied to NSA and a single early-2026 client win, which analysts flagged as potentially hard to extrapolate. Payment & Revenue Integrity is still under pressure from client migration, gross margin fell year over year, and leverage remains elevated at 7.7x, so the company still has execution and deleveraging work ahead.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 40.1%
- Shares Outstanding
- 17.07M
- Float Shares
- 6.84M
of shares held by institutions
113 13F filers
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| H&F Corporate Investors Viii, Ltd. | 3.89M | 0 |
| Ares Management LLC | 1.86M | 0 |
| Arini Capital Management Ltd | 1.53M | 0 |
| Public Investment Fund | 1.28M | 0 |
| Blackrock, Inc. | 772.83K | ▲ 49.61K |
| Vanguard Capital Management LLC | 586.13K | ▲ 163.09K |
| Vanguard Group Inc | 584.47K | ▲ 66.70K |
| Cpv Partners, LLC | 495.26K | 0 |
| Prudential Financial Inc | 377.40K | ▲ 23.50K |
| Jpmorgan Chase & Co | 353.80K | ▲ 349.56K |
| Point72 Asset Management, L.P. | 255.12K | ▲ 216.12K |
| Geode Capital Management, LLC | 241.93K | ▲ 16.78K |
Held by 131 ETFs
Biggest fund positions in CTEV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | ARES MANAGEMENT LLC | buy | 13,587 |
| Nov 11, 26 | ARES MANAGEMENT LLC | buy | 13,587 |
| Nov 11, 26 | Dalton Travis | buy | 5,110 |
| Nov 10, 26 | Klein Michael Stuart | sell | 5,500 |
| Nov 11, 26 | Klein Michael Stuart | sell | 40,000 |
| Nov 12, 26 | Klein Michael Stuart | sell | 20,067 |
| Apr 29, 26 | Klein Michael Stuart | other | 0 |
| Nov 10, 26 | ARES MANAGEMENT LLC | buy | 65,579 |
| Nov 9, 26 | ARES MANAGEMENT LLC | buy | 50,000 |
| Nov 10, 26 | ARES MANAGEMENT LLC | buy | 65,579 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CTEV coverage
Recent articles, reports, and earnings notes.
No research on CTEV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTEV report →Claritev Corporation Announces Participation in Upcoming Events
globenewswire.com · Nov 20
Saudi Arabia's Wealth Fund Has 80% of Its U.S. Stock Portfolio in SpaceX
247wallst.com · Nov 18
Claritev (NYSE:CTEV) Major Shareholder Acquires $1,221,000.00 in Stock
defenseworld.net · Nov 15
Claritev (NYSE:CTEV) vs. OneMedNet (NASDAQ:ONMD) Head-To-Head Analysis
defenseworld.net · Nov 11
Claritev Corporation (CTEV) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
What Claritev (CTEV) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
Claritev Corporation (CTEV) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 9
Claritev Corporation Reports Third Quarter 2026 Results
globenewswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.